Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487353 | 1.00 | POLB (0.46) | POLBCES2CES1ALDH1A1KMT2A | |
| SCHEMBL28319862 | 0.83 | NPC1 (0.44) | POLBALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL29556906 | 0.82 | CES2 (0.44) | POLBCES2CES1ALDH1A1KMT2A | |
| SCHEMBL14639033 | 0.81 | LMNA (0.50) | POLBALDH1A1KMT2ATSHRL3MBTL1 | |
| SCHEMBL27981110 | 0.80 | CTSD (0.51) | POLBKMT2ATSHRHPGDRAB9A | |
| SCHEMBL27874622 | 0.80 | KMT2A (0.42) | ALDH1A1KMT2AHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL27152360 | 0.80 | PKM (0.48) | CES2CES1ALDH1A1KMT2AHPGD | |
| SCHEMBL27874678 | 0.80 | ALDH1A1 (0.38) | ALDH1A1KMT2ATSHRHPGDSMN1; SMN2 | |
| SCHEMBL4346405 | 0.78 | PLK1 (0.50) | POLBALDH1A1KMT2ATSHRHPGD | |
| SCHEMBL5318618 | 0.77 | CES2 (0.65) | POLBCES2CES1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110423198-B | Acid catalysis synthesis method and application of phenoxyl acetate derivative | 南京师范大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-108658812-B | Alpha-alkoxy-alpha-nitrogen oxyacetate derivative and synthesis method and application thereof | 华东师范大学 | 2020-12-22 | — | — | CN | disclosed |
| US-10207984-B2 | Cyclopropyl derivatives and methods of use | EMORY UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20160244403-A1 | Cyclopropyl Derivatives and Methods of Use | UNIV EMORY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244403-A1 | Cyclopropyl Derivatives and Methods of Use | UNIV EMORY (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2699539-A2 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | Emory University (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045936-A1 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045936-A1 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2014-02-13 | — | — | US | disclosed |
| CN-101412738-B | Novel chiral iron complex, and preparation and use thereof | ZHEJIANG JIUZHOU PHARM CO LTD | 2013-04-24 | — | — | CN | disclosed |
| WO-2012145234-A2 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | EMORY UNIVERSITY (US) | 2012-10-26 | — | — | WO | disclosed |
| CN-101412738-A | Novel chiral iron complex, and preparation and use thereof | ZHEJIANG JIUZHOU PHARMACEUTICA (CN) | 2009-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244403-A1 | Cyclopropyl Derivatives and Methods of Use | CNR2, FKBP8, FKBP5 | POLB 4532/4885CES2 376/4885CES1 1423/4885 |
| US-10207984-B2 | Cyclopropyl derivatives and methods of use | CNR2, FKBP8, FKBP5 | POLB 4532/4885CES2 376/4885CES1 1423/4885 |
| US-20140045936-A1 | CYCLOPROPYL DERIVATIVES AND METHODS OF USE | CNR2, FKBP8, FKBP5 | POLB 4532/4885CES2 376/4885CES1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.